A first-in-patient, multi-ascending dose trial of PRS-343 for the treatment of HER-2 positive solid tumors
Phase of Trial: Phase I
Latest Information Update: 02 Oct 2017
At a glance
- Drugs PRS 343 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pieris Pharmaceuticals
- 02 Oct 2017 According to a Pieris Pharmaceuticals, Inc. media release, the first patient has been dosed in this trial.
- 02 Oct 2017 According to a Pieris Pharmaceuticals, Inc. media release, status changed from planning to recruiting.
- 09 Aug 2017 According to a Pieris Pharmaceuticals media release, the company expects to to dose first patient in this trial very soon.